A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
News|Articles|October 1, 2026
Top headlines in women's health from September 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Joshua Fitch, Senior Editor
A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
Advertisement
Advertisement
September was one of the busiest months of the year for Contemporary OB/GYN, with new clinical guidance, society statements, research findings, conference data, and a major new content launch all landing in the same 30 days. Below is a recap of the top stories from the month.
Related to this article
AJOG research shows a cytokine storm could be detectable in maternal blood before the clinical onset of AFE.
CDC data show gestational hypertension rose 73% from 2016 to 2024, affecting 1 in 10 US mothers giving birth.
Missed the updated IDSA histoplasmosis guideline? This easy-to-read FAQ covers what clinicians caring for pregnant patients need to know.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Maternal RSV immunization creates an important opportunity for obstetric and pediatric clinicians to coordinate newborn prevention strategies, according to Kevin Ault, MD.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
Advertisement
Advertisement